Buy & Sell Amgen, Inc. (AMGN) – Amgen, Inc. Price Today
Aura AI Summary
Key Stats
- $191.09BMarket Cap
- HealthSector
- -11.58%3M Drawdown
- $236.37BEnterprise Value
- 2.85%Dividend Yield
- 87% Buy | 13% SellTrading Activity
- 74 daysTypical Hold Time
Amgen, Inc. (AMGN) is currently valued at a market capitalization of $191.09B, with an enterprise value of $236.37B. Over the past 52 weeks, Amgen, Inc. has traded between a low of $271.18 and a high of $388.16, highlighting its annual price range. Over the past three months, Amgen, Inc. has recorded a drawdown of -11.58%, reflecting recent price volatility. Amgen, Inc. offers a dividend yield of 2.85%, with the most recent dividend of $2.52 paid on 15 May 26. On average, investors hold Amgen, Inc. for approximately 74 days, indicating typical investor behavior on the platform.
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Most Recent News
New data show Lyell's ronde-cel CAR T-cell therapy is safe and effective for large B-cell lymphoma.
Lyell Immunopharma presented updated safety and translational data for its CAR T-cell therapy, ronde-cel, in treating relapsed or refractory large B-cell lymphoma (LBCL). Over 100 patients treated showed no severe cytokine release syndrome (CRS) and ...
SpaceX shares debut at $150, rising to $165, valuing the company near $2 trillion.
SpaceX began trading on the stock market at $150 per share, above its IPO price of $135, marking the largest public offering in history and valuing the company at about $1.96 trillion. The shares quickly rose to $165, reflecting strong demand that ex...
Space ETFs drop sharply as SpaceX debuts in record $1.77T IPO, investors rotate funds into the new stock.
Space ETFs fell significantly on the day SpaceX launched its IPO, priced at $135 per share with a $1.77 trillion valuation, raising $75 billion in the largest IPO ever. The sell-off reflects investors rotating out of other space stocks to buy SpaceX ...